Compare NUVB & ARI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | ARI |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | 307 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2009 |
| Metric | NUVB | ARI |
|---|---|---|
| Price | $5.65 | $10.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $11.38 | $11.00 |
| AVG Volume (30 Days) | ★ 4.3M | 1.5M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 9.31% |
| EPS Growth | N/A | ★ 183.51 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $271,589,000.00 |
| Revenue This Year | $203.82 | N/A |
| Revenue Next Year | $58.18 | N/A |
| P/E Ratio | ★ N/A | $67.69 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.87 | $9.49 |
| 52 Week High | $9.75 | $11.24 |
| Indicator | NUVB | ARI |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 49.43 |
| Support Level | $5.22 | $10.66 |
| Resistance Level | $6.06 | $11.14 |
| Average True Range (ATR) | 0.38 | 0.19 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 89.06 | 51.14 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.